Hamada et al., evaluated the efficacy, immunogenicity and safety of monovalent and bivalent lipid nanoparticle-mRNA vaccine, DS-5670, against SARS-CoV-2 variants in two randomized trials. Findings show DS-5670 is as effective as existing mRNA vaccines, with broad neutralization activity across omicron sub-lineages.
- Shunsuke Hamada
- Miharu Suda
- Fumihiko Takeshita
